|
| Press Releases |
|
 |
|
| Thursday, March 21, 2019 |
|
|
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease |
| Biogen and Eisai, Co., Ltd. announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease dementia. more info >> |
|
| Tuesday, June 28, 2022 |
|
|
E.Design Insurance and Eisai Enter Into Business Alliance |
| E.design Insurance Co., Ltd., a direct non- life insurance company of the Tokio Marine Group, and Eisai Co., Ltd. announced today that both companies have entered into a business alliance agreement aiming to realize a society where people can safely enjoy driving for a longer period of their lives in anticipation of the advent of super-aging society, under the theme of "Improving Brain Health (brain performance) for Safe Driving." more info >> |
|
| Friday, June 24, 2022 |
|
|
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases |
| Eisai Co., Ltd. announced today that Eisai has signed the Kigali Declaration announced at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) on June 23, 2022 in Kigali, the capital of the Republic of Rwanda, and expressed Eisai's continued support for the elimination of NTDs towards the achievement of a road map for NTDs 2021-2030 launched by the World Health Organization (WHO). more info >> |
|
|
エーザイ、顧みられない熱帯病制圧に向けた官民パートナーシップ「キガリ宣言」に署名 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、2022年6月23日にルワンダ共和国の首都キガリで開催された「マラリアと顧みられない熱帯病（Neglected Tropical Diseases: NTDs）に関するキガリ・サミット」において発表された「キガリ宣言」に署名し、世界保健機関（WHO）による「NTDsロードマップ（2021－2030）」の達成に向けて、今後もNTDs制圧支援を継続することを表明しました。 more info >> |
|
| Thursday, June 23, 2022 |
|
|
エーザイ、東京都文京区による2022年度認知症検診事業において、「のうKNOW」を活用した脳の健康度測定を実施 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、東京都文京区(以下、文京区)が実施する2022年度認知症検診事業において、新たに導入された成果連動型民間委託契約方式の下、当社が開発したブレインパフォーマンス（脳の健康度）のセルフチェックツール「のうKNOW(R)」（非医療機器）を用いた脳の健康度測定が実施されることをお知らせします。 more info >> |
|
| Wednesday, June 22, 2022 |
|
|
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal |
| Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (Abeta) protofibril antibody lecanemab in people living with early Alzheimer's disease (AD) using a validated disease simulation model. more info >> |
|
|
エーザイ、「レカネマブ」の潜在的な経済価値について査読学術専門誌Neurology and Therapy誌に掲載 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、早期アルツハイマー病（AD）当事者様に対する抗アミロイドβ（Aβ）プロトフィブリル抗体レカネマブ（開発品コード：BAN2401）の潜在的な経済価値について、米国における医療費支払者観点および社会的観点から、検証済の疾患シミュレーション・モデル（AD Archimedes Condition Event simulation：AD ACE モデル 1,2,3）を用いて推定した初期段階の評価結果が査読学術専門誌Neurology and Therapy 誌に掲載されたことをお知らせします。 more info >> |
|
| Friday, June 17, 2022 |
|
|
エーザイ、人事異動ならびに組織改編（2022年6月17日付）を発表 |
| エーザイ株式会社は本日、人事異動ならびに組織改編（2022年6月17日付）を以下のとおり発表しました。 more info >> |
|
| Thursday, June 9, 2022 |
|
|
エーザイ、2023年3月期業績予想（IFRS）の修正に関するお知らせ |
| 直近の業績の動向等を踏まえ、2022年5月13日に公表した2023年3月期（2022年4月1日から2023年3月31日）の業績予想を下記のとおり修正しますのでお知らせします。 more info >> |
|
| Monday, June 6, 2022 |
|
|
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting |
| Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
analytica Hanoi 2026 Makes Its Debut, Bringing the Global Science and Laboratory Platform to Northern Vietnam
Feb 26, 2026 02:52: JST
|
|
|
Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreement at EGM
Feb 25, 2026 21:59: JST
|
|
|
Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreement at EGM
Feb 25, 2026 21:59 JST
|
|
|
雲頂新耀股東特別大會通過商業化服務協議等決議案
Feb 25, 2026 20:59 HKT/SGT
|
|
|
云顶新耀股东特别大会通过商业化服务协议等决议案
Feb 25, 2026 20:59 HKT/SGT
|
|
|
Doubleview Gold Corp. Reports Updated Mineral Resource Estimate as of February 25, 2026 Including a Copper Equivalent Mineral Resource: 609 (Mt) of Measured and Indicated Resources at 0.43% CuEq containing CuEq 5.82 Billion lbs. 503 (Mt) of Inferred Resources at 0.41% CuEq containing CuEq 4.57 Billion lbs
Feb 25, 2026 20:59 HKT/SGT
|
|
|
Toyota Launches New bZ4X Touring BEV Focused on Driving Performance and Spaciousness in Japan
Feb 25, 2026 21:58 JST
|
|
|
DOCOMO and Keio University Demonstrate World's First Stable, High-Fidelity Robot Teleoperation via Commercial 5G Using Low-Latency Slicing
Feb 25, 2026 21:01 JST
|
|
|
analytica Hanoi 2026 Makes Its Debut, Bringing the Global Science and Laboratory Platform to Northern Vietnam
Feb 25, 2026 19:57 HKT/SGT
|
|
|
DOCOMO Successfully Demonstrates AI Application Operation Using Virtualized Radio Access Network (vRAN) Infrastructure
Feb 25, 2026 20:50 JST
|
|
|
DOCOMO Begins Commercial Deployment of Agentic AI System for Network Maintenance Using One of the World's Largest Datasets
Feb 25, 2026 20:40 JST
|
|
|
Champion REIT Delivers Resilient Performance, Proactive Tenant Mix Optimisation Drives Sustainable Development
Feb 25, 2026 19:30 HKT/SGT
|
|
|
冠君產業信託於挑戰中彰顯韌性 積極優化租戶組合推動持續發展
Feb 25, 2026 19:30 HKT/SGT
|
|
|
周大福人壽支持《財政預算案》有關跨境安老、落實《香港可持續披露準則》以及推動體育普及化、盛事化等措施
Feb 25, 2026 18:07 HKT/SGT
|
|
|
HKTDC welcomes the 2026-27 Budget
Feb 25, 2026 17:29 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
